Media

Press releases

23May

Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation

13May

Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation

21Apr

Regulatory press release

Hansa Biopharma interim report January – March 2022

President and CEO

Senior Vice President, Chief Commercial Officer

Senior Vice President, Chief Scientific Officer, Research and Development

Senior Vice President, Chief Financial Officer

Senior Vice President, Chief Medical Officer

Senior Vice President, Chief Human Resources Officer